JP2013538863A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538863A5 JP2013538863A5 JP2013532104A JP2013532104A JP2013538863A5 JP 2013538863 A5 JP2013538863 A5 JP 2013538863A5 JP 2013532104 A JP2013532104 A JP 2013532104A JP 2013532104 A JP2013532104 A JP 2013532104A JP 2013538863 A5 JP2013538863 A5 JP 2013538863A5
- Authority
- JP
- Japan
- Prior art keywords
- fii
- fibrinogen
- fviia
- medicament according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 28
- 108010049003 Fibrinogen Proteins 0.000 claims 16
- 102000008946 Fibrinogen Human genes 0.000 claims 16
- 229940012952 fibrinogen Drugs 0.000 claims 16
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 14
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 14
- 239000003114 blood coagulation factor Substances 0.000 claims 14
- 239000008280 blood Substances 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 206010053567 Coagulopathies Diseases 0.000 claims 5
- 208000024659 Hemostatic disease Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 208000034158 bleeding Diseases 0.000 claims 3
- 230000000740 bleeding effect Effects 0.000 claims 3
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- 230000009852 coagulant defect Effects 0.000 claims 3
- 208000012908 vascular hemostatic disease Diseases 0.000 claims 3
- 206010053476 Traumatic haemorrhage Diseases 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims 2
- 230000023597 hemostasis Effects 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101001052793 Homo sapiens GDP-L-fucose synthase Proteins 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 102000050085 human TSTA3 Human genes 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39022410P | 2010-10-06 | 2010-10-06 | |
| US61/390,224 | 2010-10-06 | ||
| PCT/EP2011/066241 WO2012045569A1 (en) | 2010-10-06 | 2011-09-19 | Factor ii and fibrinogen for treatment of haemostatic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013538863A JP2013538863A (ja) | 2013-10-17 |
| JP2013538863A5 true JP2013538863A5 (cg-RX-API-DMAC10.html) | 2014-11-20 |
| JP6000259B2 JP6000259B2 (ja) | 2016-09-28 |
Family
ID=44677879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532104A Expired - Fee Related JP6000259B2 (ja) | 2010-10-06 | 2011-09-19 | 止血障害治療用第ｉｉ因子およびフィブリノーゲン |
Country Status (16)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12171463B2 (en) | 2008-10-03 | 2024-12-24 | Femasys Inc. | Contrast agent generation and injection system for sonographic imaging |
| DK2624859T3 (en) | 2010-10-06 | 2017-06-06 | Medimmune Ltd | FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY |
| IL230150A0 (en) * | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing zymogens |
| SG10201912497WA (en) * | 2017-02-09 | 2020-02-27 | Csl Behring Gmbh | A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings |
| CN116059431A (zh) * | 2021-10-29 | 2023-05-05 | 丁琴琴 | 一种含凝血因子的双层止血敷料及其制备方法 |
| WO2023220412A1 (en) * | 2022-05-13 | 2023-11-16 | Cedars-Sinai Medical Center | Hemostatic monitor |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3165600D1 (en) * | 1980-01-28 | 1984-09-27 | Baxter Travenol Lab | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
| US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
| DE4430204A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung |
| SI0796623T1 (en) * | 1996-03-20 | 2005-10-31 | Baxter Aktiengesellschaft | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| AT409334B (de) | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
| US7094428B2 (en) | 2000-06-16 | 2006-08-22 | The University Of Medicine And Dentistry Of New Jersey | Hemostatic compositions, devices and methods |
| US6825323B2 (en) | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
| CA2437015A1 (en) | 2001-02-05 | 2002-08-15 | Novo Nordisk Health Care Ag | Combined use of factor vii polypeptides and factor ix polypeptides |
| US20060025336A1 (en) | 2001-07-16 | 2006-02-02 | Novo Nordisk A/S | Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides |
| IL159622A0 (en) * | 2001-07-20 | 2004-06-01 | Novo Nordisk Healthcare Ag | Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
| US20040101546A1 (en) * | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
| EP1587424A4 (en) | 2002-12-31 | 2012-01-25 | Marinepolymer Tech Inc | Bleeding Compounds and their uses |
| GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| EP2165711B1 (en) | 2004-05-27 | 2014-05-21 | Baxter International Inc. | Methods for treating bleeding disorders using sulfated polysaccharides |
| WO2006114105A2 (en) | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| MX336958B (es) | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| RU2008139428A (ru) * | 2006-03-06 | 2010-05-20 | Хьюмэджин, Инк. (Us) | Способ получения рекомбинантного тромбина и фибриногена человека |
| US20080014251A1 (en) | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
| US20090148502A1 (en) | 2006-10-23 | 2009-06-11 | Hemo Nanoscience, Llc | Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding |
| EP1935429A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates |
| EP2131776A1 (en) | 2007-03-30 | 2009-12-16 | Thrombodyne Inc. | Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue |
| RU2571931C2 (ru) | 2007-04-13 | 2015-12-27 | Каталист Биосайенсис, Инк. | Полипептиды на основе модифицированного фактора vii и их применение |
| US8852558B2 (en) | 2008-03-11 | 2014-10-07 | Materials Modification, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst |
| CA2740079A1 (en) | 2008-10-08 | 2010-04-15 | Thrombodyne, Inc. | Methods of making concentrated fibrinogen- and platelet-containing compositions |
| DK2624859T3 (en) | 2010-10-06 | 2017-06-06 | Medimmune Ltd | FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY |
-
2011
- 2011-09-19 DK DK11761051.9T patent/DK2624859T3/en active
- 2011-09-19 SG SG2013021498A patent/SG188639A1/en unknown
- 2011-09-19 CN CN2011800479754A patent/CN103221061A/zh active Pending
- 2011-09-19 EP EP11761051.9A patent/EP2624859B1/en not_active Revoked
- 2011-09-19 PL PL11761051T patent/PL2624859T3/pl unknown
- 2011-09-19 MX MX2013003715A patent/MX343784B/es active IP Right Grant
- 2011-09-19 JP JP2013532104A patent/JP6000259B2/ja not_active Expired - Fee Related
- 2011-09-19 RU RU2013120033A patent/RU2606155C2/ru not_active IP Right Cessation
- 2011-09-19 AU AU2011313505A patent/AU2011313505B2/en not_active Ceased
- 2011-09-19 BR BR112013008034A patent/BR112013008034A2/pt not_active IP Right Cessation
- 2011-09-19 WO PCT/EP2011/066241 patent/WO2012045569A1/en not_active Ceased
- 2011-09-19 HU HUE11761051A patent/HUE033204T2/en unknown
- 2011-09-19 CA CA2812888A patent/CA2812888A1/en not_active Abandoned
- 2011-09-19 US US13/877,854 patent/US9433664B2/en not_active Expired - Fee Related
- 2011-09-19 SG SG10201508159SA patent/SG10201508159SA/en unknown
- 2011-09-19 KR KR1020137008520A patent/KR20130136988A/ko not_active Ceased
- 2011-09-19 ES ES11761051.9T patent/ES2625153T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Messina et al. | Hemodynamic changes associated with spinal and general anesthesia for hip fracture surgery in severe ASA III elderly population: a pilot trial | |
| Lambourne et al. | Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate | |
| Reed et al. | Uses of tranexamic acid | |
| Lillo-Le Louët et al. | Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation | |
| Holmström et al. | Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A–a two‐centre experience | |
| WO2015066700A3 (en) | Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation | |
| Olsson et al. | Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation | |
| Miesbach et al. | Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study | |
| Faust et al. | Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report | |
| Thipparampall et al. | The effect of different dose regimens of tranexamic acid in reducing blood loss during hip surgery | |
| JP2014529606A5 (cg-RX-API-DMAC10.html) | ||
| Yang et al. | Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage | |
| Windyga et al. | Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors. | |
| Dager et al. | Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants | |
| Majeed et al. | Effectiveness and outcome of management strategies for dabigatran-or warfarin-related major bleeding events | |
| Mauser‐Bunschoten et al. | Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors | |
| Filsoufi et al. | Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII | |
| Ashikhmina et al. | Type A aortic dissection in a patient on dabigatran: hemostasis post circulatory arrest | |
| RU2013120033A (ru) | Фактор ii и фибриноген для лечения гемостатических нарушений | |
| Awad et al. | Dabigatran, intracranial hemorrhage, and the neurosurgeon | |
| Diener | Pro:“The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.” | |
| Spira et al. | Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A | |
| JP2020506880A5 (cg-RX-API-DMAC10.html) | ||
| Hacihanefioglu et al. | Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard–Soulier syndrome | |
| Berndtson et al. | The epidemic of pre-injury oral antiplatelet and anticoagulant use |